Published in Vaccine Weekly, October 22nd, 2008
The Phase I study is expected to yield important information about the safety and immunogenicity – or ability to generate an immune response -- of VaxInnate's hemagglutinin (HA)-flagellin flu vaccine candidate. The study is taking place at the University of Rochester in New York. Results are expected in early 2009.
The HA vaccine candidate links the hemagglutinin (HA) antigen, which has been the key protective component in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly